Volume 8, Number 6, 439-440, DOI: 10.1007/s11912-006-0072-y

Intraperitoneal chemotherapy for frontline ovarian cancer therapy: Vindicated or vilified?

Robert L. Coleman

View Related Documents

Abstract

A regimen of IV paclitaxel plus IP cisplatin and paclitaxel improves both PFS and OS in patients with optimally cytoreduced stage III ovarian cancer relative to IV cisplatin and paclitaxel.

Fulltext Preview

Image of the first page of the fulltext document